Description

INTENDED USE
The Aimatis HBsAg Rapid Test is an In-Vitro, qualitative, one-step immunochromatographic assay for the detection of Hepatitis B virus Surface Antigen in Serum/Plasma/Whole Blood.

SUMMARY
Viral hepatitis is a systemic disease primarily involving the liver. Most cases of acute viral hepatitis are caused by Hepatitis A virus, Hepatitis B virus (HBV), or Hepatitis C virus. The complex antigen found on the surface of HBV is called HBsAg. The presence of HBsAg in serum or plasma is an indication of an active Hepatitis B infection, either acute or chronic. The antibody to HBsAg, may not become detectable for 3-6 months after acute infection. It is associated with the resolution of the illness. This antibody is recognized as the marker of immunity to HBV. As a result, vaccination against HBV was introduced to control the morbidity and mortality associated with the virus. As part of the World Health Organization (W.H.O) program for the control of hepatitis B, many people, especially newborn infants, receive vaccination. Unfortunately, approximately 5-15% of healthy immunocompetent individuals either do not exhibit an antibody response to the existing recombinant vaccination or respond too poorly.